ArticleJournal of community hospital internal medicine perspectives2026
Evolving Trends and Racial Disparities in Alcohol Associated Liver Disease (ALD), Metabolic Dysfunction Associated Steatohepatitis (MASH) and Hepatitis C Viral Infection (HCV) as Etiology of Liver Transplantation: Past, Present, and Future Projections.
Article in Journal of community hospital internal medicine perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver transplantation remains the definitive treatment for end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). While hepatitis C virus (HCV) was historically the leading indication for liver transplant, the introduction of direct-acting antivirals (DAAs) has drastically reduced HCV-related ESLD. In contrast, metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD) have emerged as predominant causes of liver transplantation. This study evaluates racial and ethnic disparities in liver transplantation indications from 2004 to 2023 and projects future trends through to 2040. Methods: De-identified data from the Standard Transplant Analysis and Research (STAR) files of the United Network for Organ Sharing (UNOS) database were analyzed to assess temporal trends in the proportion of ALD, HCV, and MASH as etiologies of liver transplant indications using Joinpoint regression. The annual percentage change (APC) in the proportion of etiologies of liver transplantation were reported with a significance level at a p-value of 0.5. Future projections were estimated using the Box-Jenkins methodology of Autoregressive Integrated Moving Average (ARIMA) modelling. Trends were stratified by race/ethnicity to evaluate disparities. Results: The proportion of liver transplantation attributed to ALD has risen significantly across all racial groups, with American Indian/Alaska Native (AIAN) individuals experiencing the steepest increase. By 2040, ALD is projected to account for 80% of liver transplantation in AIAN populations. MASH-related liver transplantation is also increasing, particularly among Hispanic and White individuals, with projections reaching approximately 40% by 2040. In contrast, HCV-related liver transplantation has sharply declined across all racial groups likely due to the impact of DAAs, however, the Black population continues to experience disproportionately higher rates of HCV-related ESLD. Conclusion: The shifting landscape of liver transplantation etiologies highlights the growing burden of ALD and MASH, emphasizing the need for targeted prevention strategies. Persistent racial disparities in liver transplant access and outcomes underscore systemic healthcare inequities. Addressing these disparities through equitable healthcare policies, early intervention programs, and improved transplant access is crucial to ensuring fair distribution of transplant resources and improved outcomes for all populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.